Table 4.
Pharmacokinetics of each drug in patients receiving OSL monotherapy or TCAD therapy
| OSL |
AMT |
RBV |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subject | Age | Dosea, mg |
Cmax, ng/ml |
Cmin, ng/ml |
AUC0–last, hxng/ml |
Dosea, mg |
Cmax, ng/ml |
Cmin, ng/ml |
AUC0–last, hxng/ml |
Dosea, mg |
Cmax, ng/ml |
Cmin, ng/ml |
AUC0–last, hxng/ml |
| 1-1b | 17 | 50 | 467.7 | 226.3 | 1,497.1 | – | – | – | – | – | – | – | – |
| 1-2c | 72 | 50 | 165.6 | 112.1 | 304.0 | 75 | 788.6 | 615.9 | 1,456.5 | – | – | – | – |
| 2-1d | 58 | 50 | 1,564.9 | 1,377.4 | 5,683.1 | 37.5 | 560.2 | 303.0 | 1,662.9 | 200 | 670.8 | 288.6 | 2,161.6 |
| 2-3 | 9 | 40 | 324.8 | 184.6 | 1,010.5 | 50 | 1,161.5 | 915.7 | 4,405.9 | 150 | 1,466.7 | 1,146.0 | 5,369.0 |
| 2-4 | 6 | 40 | 260.6 | 133.6 | 768.8 | 50 | 626.7 | 398.3 | 2,215.5 | 150 | 1,643.0 | 708.2 | 5,397.1 |
a
lndicated dose was administered every 8 h.
b
Subject 1-1 received oseltamivir (OSL) monotherapy.
c
Subject 1-2 had insufficient sample for ribavirin (RBV) level analysis.
d
Subject 2-1 had renal impairment. AMT, amantadine; AUC0–last, total exposure up to the last measured concentration; Cmax, maximum observed plasma concentration; Cmin, minimum observed plasma concentration; TCAD, triple combination antiviral drug.